Impact of HER2-low and HER2-zero status on outcomes: A multicenter propensity-score matched study

被引：0
|
作者：
Cha, C. D. [1 ]
Kim, K. E. [2 ]
Kim, J. [3 ]
Um, E. [4 ]
Choi, N. [5 ]
Lee, J. [2 ]
Gwak, G. [3 ]
Kim, J. I. [4 ]
Chung, M. S. [1 ]
机构：
[1] Hanyang Univ, Coll Med, Surg, Seoul, South Korea
[2] Inje Univ, Coll Med, Surg, Haeundae Paik Hosp, Busan, South Korea
[3] Inje Univ, Sanggye Paik Hosp, Sch Med, Surg, Seoul, South Korea
[4] Inje Univ, Ilsan Paik Hosp, Ilsan, South Korea
[5] Hanyang Univ, Med Res Collaborating Ctr, Seoul, South Korea
来源：
BREAST | 2025年 / 80卷
关键词：
D O I：
10.1016/j.breast.2025.104089
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P248
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 h+HER2-breast cancer: a retrospective analysis
    Kook, Yoonwon
    Lee, Young-jin
    Chu, Chihhao
    Jang, Ji Soo
    Baek, Seung Ho
    Bae, Soong June
    Cha, Yoon Jin
    Gong, Gyungyup
    Jeong, Joon
    Lee, Sae Byul
    Ahn, Sung Gwe
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [32] Evaluating dynamic contrast-enhanced MRI for differentiating HER2-zero, HER2-low, and HER2-positive breast cancers in patients undergoing neoadjuvant chemotherapy
    Hu, Yangling
    Li, Meizhi
    Hu, Yalan
    Wang, Mengyi
    Lin, Yingyu
    Mao, Lijuan
    Wang, Chaoyang
    Shui, Yanhong
    Song, Yutong
    Wang, Huan
    Ji, Lin
    Che, Xin
    Shao, Nan
    Zhang, Xiaoling
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2025, 30 (01)
  • [33] Prognostic Impact of HER2-Low and HER2-Zero in Resectable Breast Cancer with Different Hormone Receptor Status: A Landmark Analysis of Real-World Data from the National Cancer Center of China
    Dai, Qichen
    Feng, Kexin
    Liu, Gang
    Cheng, Han
    Tong, Xiangyu
    Wang, Xiang
    Feng, Lin
    Wang, Yipeng
    TARGETED ONCOLOGY, 2024, 19 (01) : 81 - 93
  • [34] Prognostic Impact of HER2-Low and HER2-Zero in Resectable Breast Cancer with Different Hormone Receptor Status: A Landmark Analysis of Real-World Data from the National Cancer Center of China
    Qichen Dai
    Kexin Feng
    Gang Liu
    Han Cheng
    Xiangyu Tong
    Xiang Wang
    Lin Feng
    Yipeng Wang
    Targeted Oncology, 2024, 19 : 81 - 93
  • [35] Assessment of HER2-Low Status in HER2-Mutant Breast Carcinoma
    Yang, Ellen
    Pareja, Fresia
    Rana, Satshil
    Brannon, A.
    Vanderbilt, Chad
    Dikoglu, Esra
    Grabenstetter, Anne
    Wen, Hannah
    Brogi, Edi
    Ross, Dara
    LABORATORY INVESTIGATION, 2024, 104 (03) : S313 - S315
  • [36] Development and Validation of a Deep Learning System to Differentiate HER2-Zero, HER2-Low, and HER2-Positive Breast Cancer Based on Dynamic Contrast-Enhanced MRI
    Dai, Yi
    Lian, Chun
    Zhang, Zhuo
    Gao, Jing
    Lin, Fan
    Li, Ziyin
    Wang, Qi
    Chu, Tongpeng
    Aishanjiang, Dilinuer
    Chen, Meiying
    Wang, Ximing
    Cheng, Guanxun
    Huang, Rong
    Dong, Jianjun
    Zhang, Haicheng
    Mao, Ning
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2024,
  • [37] Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib
    Sharaf, Baha
    Abu -Fares, Hala
    Tamimi, Faris
    Al-Sawajneh, Suhaib
    Salama, Osama
    Daoud, Rand
    Alhajahjeh, Abdulrahman
    Al-Lababidi, Sawsan
    Abdel-Razeq, Hikmat
    BREAST CANCER-TARGETS AND THERAPY, 2023, 15 : 541 - 548
  • [38] Comparisons of clinical characteristics, prognosis, epidemiological factors, and genetic susceptibility between HER2-low and HER2-zero breast cancer among Chinese females
    Zheng, Lu
    Zhang, Yunmeng
    Wang, Zhipeng
    Wang, Huan
    Hao, Chunfang
    Li, Chenyang
    Zhao, Yanrui
    Lyu, Zhangyan
    Song, Fangfang
    Chen, Kexin
    Huang, Yubei
    Song, Fengju
    CANCER MEDICINE, 2023, 12 (14): : 14937 - 14948
  • [39] Prognostic stratification capacity of the CPS plus EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
    Roussot, N.
    Constantin, G.
    Desmoulins, I.
    Kaderbhai, C.
    Hennequin, A.
    Mayeur, D.
    Ilie, S. M.
    Arnould, L.
    Bertaut, A.
    Eymard, J-C.
    Jouannaud, C.
    Savoye, A. M.
    Yazbek, G.
    Allouache, D.
    Delcambre, C.
    Hrab, I.
    Levy, C.
    Djezzer, C. Segura
    Deblock, M.
    Ladoire, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S285 - S285
  • [40] Impact of HER2-low and HER2-zero status on metastatic hormonal receptor-positive breast cancer patients treated with first-line aromatase inhibitors, with or without CDK4/6 inhibitors: A multicenter retrospective analysis
    Susiriwatananont, T.
    Wongkraisri, C.
    Dajsakdipon, T.
    Supavavej, A.
    Dechaphunkul, A.
    Sunpaweravong, P.
    Neesanun, S.
    Ithimakin, S.
    Dejthevaporn, T.
    Parinyanitikul, N.
    ANNALS OF ONCOLOGY, 2024, 35 : S1420 - S1420
12345